Auditor raises questions about Egalet's future
Egalet Corp. ’s independent registered public accounting firm issued a report stating “substantial doubt exists” concerning the specialty pharmaceutical company’s ability to continue as a going concern because of the structure of some of its debt.
The report by Ernst& Young was disclosed by Egalet (NASDAQ: EGLT), which specializes in developing tamper-resistant pain medicines, in documents filed with the Securities and Exchange Commission.
The Ernst& Young report noted Eaglet ’s outstanding…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: John George Source Type: news